Hampton Roads infant with rare genetic disorder in critical need of liver donor
Rhett was diagnosed at just two months' old with a rare genetic disorder, Alagille Syndrome. Only about 1 in every 30,000 babies are born with the condition, according to the National Institutes of Health. His mother, Jenna, never imagined Rhett would be part of that statistic.
At 10 months, doctors revealed his condition was compounded with liver disease and his parents also learned he would need a liver transplant.
'There's also a lot of risk with the transplant,' she says. 'And we know that the risk of a transplant outweighs keeping his liver the way it is. So, there's a mix of emotions: sadness, happiness, excitement, nervousness, all of the above.
Alagille Syndrome is known to cause narrowed and malformed bile ducts in the liver, which is one of Rhett's toughest hurdles. His condition causes jaundice, issues with his heart and eyes, and itching so severe that he scratches until he bleeds. His blood is also highly acidic.
Jenna says Rhett only weighs 16 lbs. and is on a feeding tube. His father was left with no choice but to quit his job as he can't crawl or move on his own.
For the past two months, Jenna has been searching high and low for a liver donor who could be her baby boy's perfect match.
'His perfect match would be someone that has B or O blood type,' she says. 'Negative or positive, it doesn't matter. There would need to be aged around, 18 to 60. Nonsmoker, someone with no major organ diseases or preexisting conditions like diabetes or high blood pressure. No major abdominal surgeries; no illicit drug use. And someone that is willing to do that.'
If you think you may be a match or know of someone who could be a match, you can contact Jenna Powell at (757) 556-5182.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
9 hours ago
- Time Business News
Fast-Acting Hair Loss Treatment
Hair loss can feel like a slow erosion of confidence, especially when you see more strands on your pillow or in the shower than you remember. Modern life, stress, and environmental factors can accelerate the process, making it challenging to maintain healthy, strong hair. The good news is that science-backed solutions now target thinning at the root people are realizing that waiting too long to address hair thinning only makes the recovery journey longer. Early intervention provides the best results and can help prevent permanent hair damage. According to the American Academy of Dermatology¹, hereditary hair loss affects over 80 million people in the United States, and early treatment often leads to the most noticeable improvement. This highlights the importance of addressing thinning hair before it progresses to advanced stages. Choosing a proven Hair Loss Treatment can transform early signs of loss into a healthier, fuller look. Targeting hair loss effectively requires a combination of medical precision, targeted nutrient delivery, and hormone regulation. The following solutions combine ingredients with proven clinical benefits, providing individuals with the tools they need to restore strength and volume. Cedar Oral Hair is formulated for men experiencing male pattern hair loss. This once-daily oral capsule contains Finasteride 1 mg, Minoxidil 2.5 mg, and Biotin 5 mg. The Minoxidil enhances blood circulation to the scalp, ensuring hair follicles receive the essential nutrients they need, promoting thicker growth. Finasteride works by blocking dihydrotestosterone (DHT), a hormone derived from testosterone that is the primary cause of male pattern baldness.A clinical review from the National Institutes of Health² found that combining finasteride and minoxidil yields significantly higher hair regrowth rates compared to using either treatment alone, with 94% of patients experiencing improvement. This supports Cedar Oral Hair's multi-action approach for preserving and regrowing hair. Choosing Vita Bella means more than just getting a product. The service is built around accessibility, medical expertise, and quality assurance to ensure each customer receives the best possible outcome. Every product offered by Vita Bella is backed by scientific research and tested for safety and efficacy. The formulas combine active ingredients with decades of medical evidence showing positive outcomes for individuals facing hair loss. Clients can trust that their Hair Loss Treatment is not just popular but truly effective. Hair loss does not have to be a permanent reality. With the right blend of science-backed ingredients, medical oversight, and consistent use, regrowth and restoration are achievable. Vita Bella provides more than just medication—it offers ongoing support and proven solutions tailored to each client. TIME BUSINESS NEWS
Yahoo
11 hours ago
- Yahoo
Shaker Heights cheerleader released from hospital weeks after leg amputation
SHAKER HEIGHTS, Ohio (WJW) – The Shaker Heights cheerleader whose leg needed to be amputated after an unthinkable diagnosis celebrated a big milestone on Friday. Amani Smith was released from Rainbow Babies and Children's Hospital, weeks after doctors were forced to amputate her left leg. Amani and her family are thrilled to finally be home, but her major life change is only just beginning. The 17-year-old was at cheerleading camp earlier this summer when she started complaining about a stomach ache. Within hours, she was rushed into emergency surgery. Bernie Kosar not giving up as he waits on liver transplant Doctors at the time discovered a ruptured abdominal cyst and an infection led to sepsis, a potentially deadly condition. She had a stroke during surgery and her parents said a nicked artery during the procedure cut off blood flow to her left leg for hours. Doctors were forced to amputate and she was placed on life support for nearly a week. Now, Amani has recovered enough to return home and her family is navigating the next steps as she is determined to dance again. Big Cleveland weekend: What to know about all the events All the while, the Shaker Heights community has rallied around the family. 'It feels really good. I have a good support group around me,' Amani said. 'After two months and a few days, I'm finally free.' Amani is going into her senior year of high school. So far, a GoFundMe page has raised more than $37,000 for the family, who hopes to get her a prosthetic leg. Learn how to donate right here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Wire
12 hours ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
